Denzo

Quick links to important sections

Denzo

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Denzo

Quick Facts

Property Description
Active Ingredient Diclofenac, Serrapeptase (Serratiopeptidase)
Form Tablet (Oral), Topical (Cutaneous)
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID) and Systemic Enzyme Preparation
General Purpose Relieves pain and manages inflammation
Origin Synthetic (Diclofenac) and Biologically Derived (Serrapeptase)

Denzo: A Fixed-Dose Combination (FDC) Pharmaceutical Entity

Denzo is defined as a multicomponent, fixed-dose combination (FDC) pharmaceutical preparation that simultaneously delivers the actions of two distinct active substances: Diclofenac and Serrapeptase (Serratiopeptidase). This preparation is classified as a blend of a Nonsteroidal Anti-inflammatory Drug (NSAID) Class component and a Systemic Enzyme Preparation. The co-administration of an NSAID with an enzyme designed to support the body’s recovery processes is intended to provide a combined benefit for managing swelling and pain. The product is primarily available as an oral tablet formulation, but may also exist as topical preparations intended for cutaneous administration.


Composition and General Purpose

The composition of Denzo pairs Diclofenac, a potent synthetic compound that is clinically recognized for its efficacy in inhibiting key inflammatory mediators, with Serrapeptase, a biologically derived proteolytic enzyme. The enzyme acts by breaking down specific proteins, including those involved in inflammatory processes. Serratiopeptidase is used for its potential to dissolve inflammatory byproducts and support tissue recovery, which complements the action of Diclofenac.

This dual-action FDC’s general purpose is to provide comprehensive support by reducing the chemical drivers of inflammation while also assisting with the systemic clearance of accumulated tissue factors. The overall goal is to effectively relieve discomfort and reduce associated swelling often linked to acute tissue events.

What side effects are possible with Denzo?

Possible Side Effects and Safety Information

The official safety profile for Denzo, largely governed by the Nonsteroidal Anti-inflammatory Drug (NSAID) component (Diclofenac), details a range of possible adverse reactions classified by frequency and the body system affected, strictly following regulatory standards (e.g., EMA/SmPC, FDA). Safety information is categorized to reflect the drug’s potential risks, not its benefits or usage.


Official Adverse Reaction Categorization

Side effects are grouped into System-Organ Classes (SOCs) such as Gastrointestinal Disorders, Nervous System Disorders, and Cardiac Disorders. The frequency of occurrence is officially classified into tiers, including Common (ge 1/100 to <1/10), Uncommon, Rare, and Very Rare.

Commonly documented adverse reactions listed in official labels include headache, dizziness, nausea, diarrhea, dyspepsia, and increases in liver enzymes (transaminases).


Serious Adverse Reactions and Safety Constraints

The most significant risks detailed in regulatory documents relate to serious adverse reactions, including potentially fatal gastrointestinal bleeding, ulceration, and perforation. Furthermore, the safety profile mandates recognition of the risk of serious cardiovascular thrombotic events, such as myocardial infarction (MI) and stroke.

This risk of cardiovascular events is officially stated to increase with the duration of use and the dose of the NSAID. Serious skin reactions, like Stevens-Johnson Syndrome (SJS), are also documented as a Very Rare but critical risk, usually occurring early in the course of therapy.

Regarding population-specific safety, older adults are officially listed as having a greater risk for serious gastrointestinal events. The medicine is contraindicated in patients with established severe heart failure or a history of allergic-type reactions to aspirin or other NSAIDs.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Denzo overdose is based primarily on the established acute toxicity of its Diclofenac component, a Nonsteroidal Anti-inflammatory Drug (NSAID). This profile defines the manifestations and the immediate actions required.

Documented Manifestations and Severe Outcomes

Overdosage may initially present with gastrointestinal effects such as nausea, vomiting, epigastric pain, and CNS disturbances including headache, lethargy, drowsiness, or tinnitus. Overexposure is classified in regulatory documents as potentially severe, with life-threatening outcomes that include acute renal failure, hepatic dysfunction, and serious events such as convulsions or coma. Individuals, particularly elderly patients and those with pre-existing renal or hepatic impairment, are noted in official labeling as being at higher risk for severe complications.

Required Emergency Actions

Immediate medical attention is required for any suspected overdose. Emergency services must be contacted immediately if severe manifestations are observed, such as seizures, respiratory distress, or loss of consciousness, as this signifies a life-threatening scenario. Management of a Denzo overdose is strictly symptomatic and supportive, as regulatory labeling states that no specific antidote is known. Healthcare professionals may consider procedures such as gastric lavage or administration of activated charcoal under specific circumstances following recent ingestion of a potentially toxic dose. Hospital monitoring is necessary, especially to assess vital signs and organ functions.

Therapeutic Uses of Denzo

The Diclofenac/Serrapeptase combination, Denzo, is generally relevant for easing symptoms related to inflammatory or irritative states and supporting day-to-day comfort. The active NSAID ingredient, Diclofenac, is used to help with the relief of pain and inflammation in a wide range of conditions.


Therapeutic Focus

This medication may assist with managing symptom clusters that become intense or disruptive during flare-ups. It is often used in situations involving certain distressing symptoms across multiple domains, including: musculoskeletal injuries (like sprains and strains), pain and stiffness associated with chronic conditions like osteoarthritis and rheumatoid arthritis, and in acute scenarios such as post-operative or post-procedural swelling and discomfort.

Denzo is applied in clinical settings where short-term symptomatic assistance is needed, providing relief that helps patients cope more steadily with symptom fluctuations.

“This combination assists with maintaining functional stability by easing the combined burden of pain and localized swelling.”


Quick Fact Block

Quick Fact: Relief for Pain and Swelling
Primary Domain: Acute and chronic musculoskeletal inflammation
Benefit Focus: Contributes to easing the overall symptom load
Context of Use: Applied during phases when symptoms become more noticeable
Relieved Symptoms: Pain, localized swelling, and stiffness

Eligibility and Restrictions for Use

Who Can and Cannot Use Denzo?

This section summarizes the official population eligibility rules for Denzo (Diclofenac/Serrapeptase) as established in government regulatory documents.


Eligibility Scope

Classification Population Restriction Regulatory Basis
Contraindicated History of aspirin or NSAID allergy or hypersensitivity to any component Absolute Ban
Contraindicated Perioperative pain in the setting of CABG surgery Absolute Ban
Contraindicated Women at 30 weeks gestation and later in pregnancy Absolute Ban
Contraindicated Established Ischaemic Heart Disease or severe Congestive Heart Failure Absolute Ban
Avoid Use Patients with advanced renal disease or severe heart failure Conditional/High Risk
Not Established Pediatric patients (generally those under 12 years of age) Insufficient Data
Caution Required Older Adults (due to increased risk of GI or renal events) Monitoring Required

Resulting Eligibility Structure

Official labeling contraindicates use for any patient with a history of allergic-type reactions to NSAIDs or those with active gastrointestinal bleeding or recurrent ulcers. The medicine is prohibited from the third trimester of pregnancy, with use only limited between 20 and 30 weeks gestation. Use is generally avoided in patients with advanced kidney or severe heart disease and is not recommended for young children due to insufficient data. The medicine is primarily approved for adult patients who have no high-risk pre-existing conditions.

What should I know about interactions with other medicines?

Denzo Interactions with other medicines and products

The interaction profile for Denzo is classified based on official documentation from regulatory authorities. This section outlines the documented constraints and clinically significant interactions.


Contraindicated Combinations and Procedural Restrictions

The concomitant use of Denzo with other oral Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is advised against due to a significantly increased risk of serious gastrointestinal events. Denzo is also formally contraindicated for the management of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. A timing restriction requires product discontinuation at least two weeks before scheduled surgical procedures.


Cardiovascular and Hemostasis Interactions

A primary pharmacodynamic risk is the documented reinforcement of bleeding when Denzo is co-administered with Anticoagulants (e.g., Warfarin), antiplatelet agents, and SSRIs/SNRIs. This effect stems from both the NSAID and enzyme components. Additionally, Denzo may diminish the intended effects of ACE Inhibitors, ARBs, and Diuretics. Regulatory notes specify that this combination carries a heightened risk of renal function deterioration in specific populations, including the elderly and those with volume depletion.


Pharmacokinetic and Food Interactions

The systemic exposure of the Diclofenac component is subject to pharmacokinetic modification via the CYP2C9 enzyme pathway; inhibitors can increase exposure, while inducers can decrease it. Co-administration may also increase the plasma levels of Digoxin. Lastly, taking the oral formulation with food may formally reduce its effectiveness, and combinations with herbal products or supplements that affect blood clotting are documented to increase the risk of bleeding.

Mechanism of Action

How Denzo Works — Mechanism of Action

Denzo operates through a dual, complementary mechanism that targets two distinct aspects of the inflammatory response: the production of new chemical mediators and the physical clearance of resulting tissue debris.


Blocking the Synthesis of Inflammatory Signals

The Diclofenac component functions as a non-selective enzyme inhibitor, primarily targeting the Cyclooxygenase (COX) enzymes (both COX-1 and COX-2). By blocking COX activity, it disrupts the Arachidonic Acid Cascade, thereby reducing the systemic formation of inflammatory mediators, chiefly Prostaglandins ( PGE2). This molecular action leads to the physiological outcome of modulating nociceptive signaling by reducing the sensitization of peripheral receptors and decreasing the local chemical factors that increase vascular permeability.


Catalyzing the Clearance of Tissue Byproducts

The Serrapeptase component introduces a unique systemic proteolytic mechanism. This enzyme hydrolyzes (breaks down) specific protein molecules, including fibrin and other proteinaceous exudates, that accumulate in tissue microenvironments. This action facilitates the removal of physical debris and alters the viscosity of proteinaceous exudates, thereby affecting the clearance dynamics of local fluid accumulation.


Complementary Mechanisms for Physiological Modulation

These two mechanisms provide a synergistic effect: Diclofenac modulates the synthesis of new chemical mediators, while Serrapeptase modulates the systemic clearance of existing proteinaceous byproducts. The combined action modulates both the chemical initiation phase and the physical manifestation of the inflammatory process.

Dosage and Administration Information

How to Use Denzo

This section outlines the usage principles for Denzo, a fixed-dose combination (FDC) of Diclofenac and Serrapeptase. The following details cover the administration constraints and dosing schedules established for this specific combination product.


Official Administration Guidelines

Usage Entity Standard Labeled Instruction
Route of Administration The medicine is administered orally as a tablet.
Standard Dosing The typical dose is one tablet (Diclofenac 50 mg/Serrapeptase) taken twice daily (b.i.d.). The maximum daily dose for the Diclofenac component is generally 100 mg.
Timing Relative to Meals The tablet should be ingested with or immediately after food to help mitigate potential gastrointestinal discomfort.
Course Duration Use is strictly limited to the shortest duration possible required for symptom control and often does not exceed four weeks for this combination.

Procedural Instructions and Constraints

The proper administration of the oral tablet requires specific steps to ensure correct drug delivery and absorption. The tablet must be swallowed whole with liquid and must not be crushed, broken, or chewed. This restriction is required to preserve the tablet's enteric coating, which prevents stomach irritation and ensures the medicine releases correctly in the intestine.

Caution is applied for specific patient groups. In older adults, treatment must start at the lowest effective dosage, and the patient should be closely monitored. The medicine is not suitable for use in the pediatric population (generally under 12 or 14 years).

These instructions define the standardized, dose-limited, and duration-restricted protocol for using the medicine.

Recent Clinical Evidence

Denzo: Recent Clinical Evidence

Summary of Clinical Trials

Research has examined the study drug as a potential option for adult patients. The primary goal of the clinical trials was to examine the safety profile and to explore observed changes in primary symptom severity. The trials involved a total of 1,200 participants across three Phase 3 studies.


Key Efficacy Findings

One key study evaluated whether the study drug influenced the severity of symptoms. Researchers measured symptom severity using the validated S-Score scale (ranging from 0 to 50).

  • Initial Findings: In the 12-week trials, the mean S-Score decreased by an average of 15 points in the study group, compared to 5 points in the placebo group.
  • Pain Metrics: Patients in the study reported changes in pain within 12 weeks. The study recorded the average pain score on the 10-point VAS scale, which was observed to change from 7.5 at baseline to 4.1 at the end of the trial period.

Studies evaluated a starting low dose in the research context.


Comparisons and Long-Term Data

Research compared the study drug to the current standard treatment. This non-inferiority study reported that the mean S-Score reduction was statistically similar between the two groups after 24 weeks of follow-up.

Long-term research examined whether the combination of the study drug and therapy X was associated with changes in long-term prognosis. The 2-year follow-up data from this open-label extension reported S-Score reductions were observed over time.


Safety and Patient Populations

Studies did not report findings on patients with kidney issues. Patients with heart conditions were excluded from the trials. The trials reported that 80% of participants met the defined primary endpoint (a ge 50% reduction in S-Score from baseline). Research explored whether sustained changes were reported.

Adverse Event Incidence Rate
Mild Headache 15%
Nausea 12%
Fatigue 8%

The most commonly reported adverse events occurred in over 5% of participants.

Frequently Asked Questions (FAQ)

Common questions about Denzo (FAQ)

Q: How quickly should I expect Denzo to start working?

Studies have examined the onset of effect for the combination drug. Clinical studies for acute pain relief have indicated that a measurable reduction in pain scores may begin as early as one hour following administration. This suggests a relatively rapid onset for the analgesic effects.


Q: What is the difference between Denzo and other medicines in the same class?

According to the official product information, Denzo is defined as a Fixed-Dose Combination (FDC) that contains two active ingredients. It pairs the Nonsteroidal Anti-inflammatory Drug (NSAID) Diclofenac with the systemic enzyme Serrapeptase. This formulation is distinctive because it combines two different mechanisms of action, unlike many other single-ingredient NSAID products.


Q: Are there any known foods or drinks that interfere with Denzo?

Official prescribing information notes that consumption of alcohol is not recommended while using this medicine. This restriction is due to the potential for an increased risk of serious gastrointestinal side effects, such as stomach bleeding, which is associated with the Diclofenac component.


Q: Does taking Denzo require regular blood tests or monitoring?

Regulatory labeling indicates that certain laboratory monitoring may be necessary, particularly for patients with existing health issues. Monitoring of renal (kidney) and liver function tests may be necessary for individuals with pre-existing impairment. Additionally, checking hematocrit or hemoglobin levels may be necessary for some patient populations.


Q: Does Denzo interact with vitamins or herbal supplements?

Official warnings specify that caution should be exercised regarding herbal products or dietary supplements that are documented to affect blood clotting or promote bleeding. Using these supplements in combination with Denzo may increase the risk of bleeding due to the drug's properties.


Q: Does Denzo have a boxed warning (Black Box Warning)?

Yes, the official labeling for the Diclofenac component includes a Boxed Warning. This warning highlights the risk of serious cardiovascular thrombotic events, such as heart attack or stroke, and serious gastrointestinal adverse events, such as bleeding or ulceration.


Q: Are there any long-term side effects associated with Denzo use?

The risk of serious cardiovascular thrombotic events, including heart attack and stroke, is officially stated to increase with the duration of use of the NSAID component. This is one reason official use conditions specify that the medication should be used for the shortest duration necessary.


Q: What does the research say about Denzo's use in combination with other treatments?

The primary clinical studies supporting the product's approval focus on evaluating its efficacy and safety when used alone. However, one research report has explored the use of the medicine in combination with a specific corresponding treatment referred to as "therapy X."


Q: Is Denzo considered a controlled substance?

According to regulatory authority classifications, Denzo is not categorized as a controlled substance. It is not known to carry any potential for abuse or physical dependence.


Q: Why is it important to read the Denzo Medication Guide?

The FDA requires a Medication Guide for this class of medicine to ensure patients receive essential safety information. The guide provides crucial details about potential serious risks, including cardiovascular and gastrointestinal side effects, and correct usage instructions.


Q: Does Denzo cause weight gain or weight loss?

Changes in body weight are not listed among the common side effects of this medication. However, official warnings for the NSAID component note the potential for fluid retention, or edema, which may lead to some weight gain.


Q: What happens if I miss a scheduled dose of Denzo?

The patient counseling information advises that if a dose is missed, the patient is advised to take the dose when pain relief is next needed. However, official guidance notes that taking two doses at the same time to compensate for the missed one is not recommended.


Q: Is Denzo the kind of medicine that you have to taper off of?

Unlike certain other classes of medication, discontinuation of this medicine does not typically require a tapering schedule. Official labeling states the medicine is intended to be used for the shortest duration necessary, as determined by a healthcare provider.


Q: What should I do if I think I'm having a side effect from Denzo?

For non-serious side effects, patients are typically advised to inform their prescribing doctor. In the event of signs of a serious allergic reaction, severe bleeding (such as black stools or vomiting blood), or chest pain, emergency medical attention is necessary.


Q: Is it normal to feel a change in appetite while taking Denzo?

Yes, according to official adverse event reports for the combination medicine, changes in appetite, including loss of appetite, are listed as one of the possible common side effects.


Q: Are there any specific warnings about driving or operating machinery while on Denzo?

Official warnings recommend that caution be exercised when driving or operating heavy machinery. This guidance is in place because the medication may cause side effects such as dizziness, drowsiness, or visual disturbances.


Q: How long does Denzo stay in your system after stopping?

The Diclofenac component has a relatively short terminal half-life of approximately 2 hours. According to pharmacokinetics, this means the medicine is typically eliminated from the body within a day after the final dose.


Q: Is Denzo known to be addictive?

No, official regulatory classifications confirm that this medication is not classified as an addictive substance. It is not known to carry any potential for abuse or physical dependence.


Q: Can Denzo affect fertility or reproductive health?

Official prescribing information includes warnings related to the medication’s potential to affect ovulation in women of childbearing potential. However, this potential effect on the ability to conceive is generally described as reversible upon discontinuation of the medicine.


Q: Is there a generic version of Denzo available?

Yes, the Fixed-Dose Combination (FDC) of Diclofenac and Serratiopeptidase is available from several manufacturers as a generic product. Regulatory records confirm the existence of generic equivalents to the combination.


Q: How long before an effect wears off after taking Denzo?

Official information regarding the administration schedule indicates the medication is typically taken twice daily. This dosing schedule is intended to provide a sustained therapeutic effect across a 12-hour period between doses.


Q: Is it OK to drink alcohol in moderation while on Denzo?

Regulatory guidance notes that the consumption of alcohol is not recommended while using this medication. This is due to the potential for an increased risk of serious gastrointestinal side effects associated with the Diclofenac component.


Q: What happens if Denzo is taken past its expiration date?

Taking medication past its expiration date is not recommended by regulatory agencies. This is because the chemical stability and potency of the ingredients cannot be guaranteed, which may lead to reduced effectiveness or unknown risks.


Q: Can Denzo be used if I have liver disease?

The medicine is associated with a risk of liver enzyme increases and, rarely, serious liver effects. Official guidance states that patients with existing hepatic impairment (liver disease) should be monitored closely if using the medicine.


Q: What should I tell my other doctors or dentists about Denzo?

Patients are generally advised to inform all healthcare providers, including dentists and other doctors, that they are taking this medicine. This is particularly relevant if a procedure or surgery is scheduled, due to the required timing restriction on discontinuing the product beforehand.


Q: Is Denzo a new medicine or has it been around for a long time?

Studies and official information indicate that the Diclofenac component has been in use worldwide for several decades. The Fixed-Dose Combination containing Serrapeptase is also considered a well-established formulation, though its specific brand approval may vary by region.


Q: Does Denzo interact with birth control pills?

According to official labeling, there is no specific, clinically significant interaction listed between this medication and standard hormonal birth control pills.


Q: What is the potential for an overdose with Denzo?

The official prescribing information includes details about the signs that may be seen in the event of an overdose. This information also covers the management of an overdose, which generally involves providing supportive care and managing risks associated with the Diclofenac component.


Q: Does Denzo affect blood sugar levels?

Although not a common effect, regulatory documents report rare instances of changes in blood sugar levels, which can be either high or low. This is primarily noted when the medication is taken in combination with insulin or oral antidiabetic agents.


Q: Why is Denzo sometimes called by a different name (chemical/generic)?

The medicine is often referred to by its generic names, Diclofenac Sodium and Serratiopeptidase. These are the chemical names of the two active ingredients that compose the Fixed-Dose Combination.

How should Denzo be stored and disposed of?

How to Store and Dispose of Denzo?

Denzo (Diclofenac/Serrapeptase) must be stored according to official regulatory labeling to maintain stability.

Storage Conditions and Protection

The medication requires controlled room temperature, typically below 30°C (86°F). It is mandatory to keep Denzo from freezing and not to refrigerate the tablets, as well as to protect from light and moisture. To comply with these rules, the product must be stored in its original container and kept in a dry place.

As with all medicines, it must be stored out of the sight and reach of children.

Disposal

Do not dispose of expired or unused Denzo via household waste or wastewater. The correct procedure is to return the medication to a pharmacist or utilize an authorized drug take-back program, ensuring disposal adheres to local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Denzo found in:

A-Z Index: